What Are DAYBUE Side Effects & How to Manage Diarrhea
At a Glance
The most common side effect of DAYBUE (trofinetide) is severe, osmotic diarrhea. Caregivers can manage this proactively under medical guidance by stopping routine laxatives, using loperamide and dietary fiber, adjusting G-tube hydration, and monitoring for dehydration and weight loss.
In this answer
4 sections
DAYBUE (trofinetide) is a breakthrough treatment for adults and pediatric patients 2 years of age and older with Rett syndrome [1][2]. While it offers significant potential benefits, it comes with a very common and challenging side effect: severe diarrhea. In the pivotal phase 3 LAVENDER trial, over 80% of participants experienced diarrhea [3].
Fortunately, clinical practice has shown that this side effect can often be managed through a proactive, multi-step approach that involves stopping prior laxatives, starting anti-diarrheal medications and dietary fiber early, maintaining strict hydration via safe methods (such as G-tube flushes), and temporarily adjusting the dose under medical supervision [3][4].
How DAYBUE Works and Its Efficacy
DAYBUE is the first FDA-approved medication specifically for Rett syndrome [1]. It is given as an oral liquid solution twice daily, and it can be taken with or without food [5].
Trofinetide is a synthetic version of glycine-proline-glutamate (GPE), a naturally occurring molecule in the brain derived from Insulin-like Growth Factor-1 (IGF-1) [3][1]. While the exact mechanism is still being studied, trofinetide is thought to work by reducing neuroinflammation (calming overactive immune cells in the brain) and supporting the formation and function of synapses, which are the vital connections between brain cells [6][7].
In the phase 3 LAVENDER trial, patients taking DAYBUE showed statistically significant improvements compared to those taking a placebo [3]. After 12 weeks, improvements were seen in two main areas:
- RSBQ (Rett Syndrome Behaviour Questionnaire): A caregiver-rated scale measuring core Rett symptoms like breathing issues, hand behaviors, and mood [3].
- CGI-I (Clinical Global Impression-Improvement): A physician-rated scale measuring the patient’s overall clinical status and improvement [3].
Long-term follow-up studies (such as LILAC and LILAC-2) have shown that these behavioral and communication improvements are maintained with continued use of the medication [8][9].
The Most Common Side Effect: Diarrhea
Because many people with Rett syndrome struggle with chronic constipation, the onset of severe, loose stools from DAYBUE can be a drastic and challenging shift.
Diarrhea is the most common side effect of DAYBUE, occurring in 80.6% of patients in the LAVENDER trial, compared to 19.1% of patients on a placebo [3]. It was also the most frequent reason families chose to stop the medication [8][10].
The diarrhea caused by DAYBUE is typically osmotic—meaning the medication draws excess water into the bowel [4][11]. It is usually mild to moderate in severity and is most likely to start during the first month of treatment [3][12]. Because of the rapid fluid loss, proactive management during the first few weeks is essential to prevent dehydration [12].
Concrete Strategies for Managing Diarrhea
Managing DAYBUE-induced diarrhea requires a proactive plan established with your doctor before starting the medication. Caregivers and nurses in clinical trials developed a practical approach that significantly helped patients stay on the medication [3][4]. This strategy involves five primary considerations:
1. Stop Laxatives
Many patients with Rett syndrome are on a daily bowel regimen for constipation. Because DAYBUE causes a strong laxative effect, your care team will likely recommend stopping all laxatives and stool softeners exactly when starting DAYBUE [4]. Do not stop them too early before you have the medication in hand, as this could risk dangerous bowel impaction.
2. Start Anti-Diarrheals and Fiber
Do not wait for the diarrhea to become severe. At the first sign of loose or watery stools, doctors typically recommend starting an over-the-counter anti-diarrheal medication, primarily loperamide (Imodium) [3][4]. Additionally, incorporating a daily dietary fiber supplement can help add bulk to the stool and absorb excess water in the gut [4].
3. Hydrate Safely (Addressing Dysphagia)
Because the diarrhea draws water out of the body, severe dehydration is a major risk [11]. However, since many individuals with Rett syndrome have severe dysphagia (swallowing difficulties), simply “drinking more fluids” is often not safe or possible, and forcing oral fluids can lead to aspiration. Work with your care team to establish a safe hydration protocol. For those with a G-tube, this often means calculating and adjusting daily G-tube water flushes to compensate for fluid lost in the stool.
4. Dose Titration and Adjustments
DAYBUE is dosed based on the patient’s weight [13][14]. If diarrhea remains unmanageable despite stopping laxatives and using loperamide, your doctor may recommend a dose adjustment. This could involve temporarily reducing the dose or briefly interrupting the medication until the bowel stabilizes, then slowly reintroducing it [3][4].
Important Warning: Caregivers should never independently change the dose or stop the medication without direct guidance from a healthcare provider. Doing so can dangerously affect treatment safety and efficacy.
5. Skin Care for Incontinence
Transitioning from constipation to severe, frequent diarrhea can be incredibly harsh on the skin, especially for incontinent patients in diapers. Stock up on high-quality, thick barrier creams (such as those containing zinc oxide) and apply them generously with every diaper change to proactively prevent severe skin breakdown.
Other Potential Side Effects
While diarrhea is the overwhelming primary concern, other side effects can occur:
- Vomiting and Aspiration Risk: Along with diarrhea, vomiting was one of the most common side effects reported [8][9]. For a non-ambulatory patient with breathing irregularities and poor motor control, vomiting carries a severe, life-threatening risk of aspiration pneumonia (inhaling vomit into the lungs). Discuss safe positioning techniques with your doctor and seek emergency medical care immediately if you suspect aspiration or if the patient is struggling to breathe.
- Weight Loss: Due to rapid fluid loss and potential vomiting, some patients experience weight loss [3][9]. Monitoring weight closely during the first few months is crucial. For patients who cannot stand on a standard scale, watch for changes in how clothing fits or schedule regular weight checks at a clinic equipped with a wheelchair scale.
- FPIES (Rare but Serious): While the typical diarrhea is a predictable osmotic issue, there have been rare reports of an immune-mediated reaction called Food Protein-Induced Enterocolitis Syndrome (FPIES) [11]. This can present with profound vomiting, extreme pallor (paleness), and lethargy. If you observe these severe signs, seek immediate emergency medical care.
Common questions in this guide
Why does DAYBUE cause diarrhea?
Should I stop my child's laxatives before starting DAYBUE?
How is DAYBUE-induced diarrhea treated?
How can we maintain safe hydration if my child has severe dysphagia?
What should I do if vomiting occurs while taking DAYBUE?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is our exact loperamide (Imodium) dosing plan, and should we have it on hand before her first dose of DAYBUE?
- 2.How should we adjust her G-tube water flushes to safely maintain hydration if she develops severe diarrhea?
- 3.At what point should we call you regarding her diarrhea, and what specific threshold would trigger a temporary dose adjustment?
- 4.Given her baseline swallowing difficulties, what is our emergency plan and safe positioning protocol if she experiences severe vomiting?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (14)
- 1
Trofinetide: First Approval.
Keam SJ
Drugs 2023; (83(9)):819-824 doi:10.1007/s40265-023-01883-8.
PMID: 37191913 - 2
Trofinetide: a pioneering treatment for Rett syndrome.
Parent H, Ferranti A, Niswender C
Trends in pharmacological sciences 2023; (44(10)):740-741 doi:10.1016/j.tips.2023.06.008.
PMID: 37460385 - 3
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.
Neul JL, Percy AK, Benke TA, et al.
Nature medicine 2023; (29(6)):1468-1475 doi:10.1038/s41591-023-02398-1.
PMID: 37291210 - 4
Managing Gastrointestinal Symptoms Resulting from Treatment with Trofinetide for Rett Syndrome: Caregiver and Nurse Perspectives.
Moore R, Poulsen J, Reardon L, et al.
Advances in therapy 2024; (41(4)):1305-1317 doi:10.1007/s12325-024-02782-4.
PMID: 38378975 - 5
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects.
Darwish M, Youakim JM, Harlick J, et al.
Clinical drug investigation 2022; (42(6)):513-524 doi:10.1007/s40261-022-01156-4.
PMID: 35622206 - 6
Trofinetide Improves Cognitive Function in APP/PS1 Mice by Suppressing Inflammation and Apoptosis.
Chen M, Ning Y, Yang H, Jia J
Molecular neurobiology 2025; (63(1)):129 doi:10.1007/s12035-025-05500-5.
PMID: 41269410 - 7
Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.
Hudu SA, Elmigdadi F, Qtaitat AA, et al.
Journal of clinical medicine 2023; (12(15)) doi:10.3390/jcm12155114.
PMID: 37568516 - 8
Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.
Percy AK, Neul JL, Benke TA, et al.
Med (New York, N.Y.) 2024; (5(9)):1178-1189.e3 doi:10.1016/j.medj.2024.05.018.
PMID: 38917793 - 9
Trofinetide for the treatment of Rett syndrome: Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study.
Percy AK, Neul JL, Benke TA, et al.
Med (New York, N.Y.) 2024; (5(10)):1275-1281.e2 doi:10.1016/j.medj.2024.06.007.
PMID: 39025065 - 10
Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials.
Mohammed HE, Bady Z, Haseeb ME, et al.
BMC medicine 2024; (22(1)):299 doi:10.1186/s12916-024-03506-9.
PMID: 39020317 - 11
Trofinetide-Induced Enterocolitis Syndrome in a Child with Rett Syndrome.
Jones SG, Alberty J, Bell M
Journal of child neurology 2025; 8830738251404099 doi:10.1177/08830738251404099.
PMID: 41428727 - 12
Post-marketing safety concerns with trofinetide: a disproportionality analysis of the first therapeutic agent for Rett syndrome based on the FDA adverse event reporting system (FAERS).
Yu X, Zhong J, Lin Z, et al.
Frontiers in pharmacology 2026; (17()):1643906 doi:10.3389/fphar.2026.1643906.
PMID: 41613782 - 13
Population Pharmacokinetic Modeling to Support Trofinetide Dosing for the Treatment of Rett Syndrome.
Darwish M, Passarell J, Maxwell K, et al.
Advances in therapy 2025; (42(2)):1026-1043 doi:10.1007/s12325-024-03056-9.
PMID: 39692836 - 14
Population Pharmacokinetics of Trofinetide in a Pediatric Population Aged 2-4 Years with Rett Syndrome.
Darwish M, Passarell J, Maxwell K, et al.
Advances in therapy 2025; (42(2)):1009-1025 doi:10.1007/s12325-024-03058-7.
PMID: 39692837
This page provides educational information on managing DAYBUE side effects for informational purposes only. Always consult your prescribing physician before adjusting doses, starting anti-diarrheals, or altering hydration protocols.
Get notified when new evidence is published on Rett syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.